Treatment for early, uncomplicated coccidioidomycosis: What is success?

John N. Galgiani, Janis E. Blair, Neil M. Ampel, George R. Thompson

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


The care of primary pulmonary coccidioidomycosis remains challenging. Such infections produce a variety of signs, symptoms, and serologic responses that cause morbidity in patients and concern in treating clinicians for the possibility of extrapulmonary dissemination. Illness may be due to ongoing fungal growth that produces acute inflammatory responses, resulting in tissue damage and necrosis, and for this, administering an antifungal drug may be of benefit. In contrast, convalescence may be prolonged by other immunologic reactions to infection, even after fungal replication has been arrested, and in those situations, antifungal therapy is unlikely to yield clinical improvement. In this presentation, we discuss what findings are clinical indicators of fungal growth and what other sequelae are not. Understanding these differences provides a rational management strategy for deciding when to continue, discontinue, or reinstitute antifungal treatments.

Original languageEnglish (US)
Pages (from-to)2008-2012
Number of pages5
JournalClinical Infectious Diseases
Issue number9
StatePublished - May 1 2020


  • Azole antifungals
  • Coccidioidomycosis
  • Symptoms
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Treatment for early, uncomplicated coccidioidomycosis: What is success?'. Together they form a unique fingerprint.

Cite this